Aclaris Therapeutics Inc (ACRS) Given Consensus Recommendation of “Hold” by Analysts
Shares of Aclaris Therapeutics Inc (NASDAQ:ACRS) have been assigned a consensus rating of “Hold” from the seven ratings firms that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $41.25.
Several research firms have commented on ACRS. JMP Securities reissued an “outperform” rating and issued a $39.00 target price on shares of Aclaris Therapeutics in a report on Friday, September 8th. Cantor Fitzgerald set a $50.00 target price on Aclaris Therapeutics and gave the stock a “buy” rating in a report on Wednesday, October 4th. Zacks Investment Research downgraded Aclaris Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, October 11th. BidaskClub raised Aclaris Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, August 16th. Finally, ValuEngine downgraded Aclaris Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, September 12th.
Aclaris Therapeutics (ACRS) traded up $1.35 during trading on Thursday, reaching $22.82. The company’s stock had a trading volume of 749,120 shares, compared to its average volume of 279,819. Aclaris Therapeutics has a twelve month low of $21.32 and a twelve month high of $33.25.
Aclaris Therapeutics (NASDAQ:ACRS) last released its earnings results on Tuesday, November 7th. The biotechnology company reported ($0.63) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.86) by $0.23. The company had revenue of $0.68 million during the quarter, compared to the consensus estimate of $2.00 million. sell-side analysts anticipate that Aclaris Therapeutics will post -2.59 EPS for the current fiscal year.
Several large investors have recently made changes to their positions in ACRS. Citigroup Inc. lifted its holdings in shares of Aclaris Therapeutics by 171.8% during the second quarter. Citigroup Inc. now owns 4,313 shares of the biotechnology company’s stock valued at $117,000 after purchasing an additional 2,726 shares in the last quarter. UBS Group AG lifted its holdings in shares of Aclaris Therapeutics by 60.4% during the first quarter. UBS Group AG now owns 4,462 shares of the biotechnology company’s stock valued at $133,000 after purchasing an additional 1,681 shares in the last quarter. Legal & General Group Plc lifted its holdings in shares of Aclaris Therapeutics by 98.3% during the second quarter. Legal & General Group Plc now owns 5,254 shares of the biotechnology company’s stock valued at $142,000 after purchasing an additional 2,605 shares in the last quarter. Cubist Systematic Strategies LLC bought a new position in shares of Aclaris Therapeutics during the third quarter valued at $142,000. Finally, Bank of Montreal Can lifted its holdings in shares of Aclaris Therapeutics by 1,793.1% during the second quarter. Bank of Montreal Can now owns 7,137 shares of the biotechnology company’s stock valued at $194,000 after purchasing an additional 6,760 shares in the last quarter. 92.10% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: This piece was originally reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this piece on another site, it was stolen and republished in violation of U.S. and international copyright & trademark laws. The original version of this piece can be read at https://theolympiareport.com/2017/12/06/aclaris-therapeutics-inc-acrs-given-consensus-recommendation-of-hold-by-analysts.html.
Aclaris Therapeutics Company Profile
Aclaris Therapeutics, Inc is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.
Receive News & Ratings for Aclaris Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.